MRNA

Moderna

Pioneering mRNA technology to create a new generation of transformative medicines

mRNA Therapeutics

Market Cap

$20.4B

Founded

2010

Headquarters

Cambridge, United States

Employees

5000-6000

Pipeline

30 programs

Publications

Patents

About

Company Overview

Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. Its historic achievement was the rapid development and global commercialization of SPIKEVAX®, a COVID-19 vaccine that proved the platform's efficacy and scalability. The company's strategy leverages its validated mRNA platform, substantial financial resources, and commercial infrastructure to build a durable portfolio of vaccines and therapeutics, aiming to address a wide spectrum of diseases with high unmet need.

Therapeutic Focus

Infectious DiseasesOncologyRare DiseasesAutoimmune Disorders

Key Facts

Founded2010

HeadquartersCambridge, United States

Employees5000-6000

ListedNASDAQ: MRNA

Market Cap$20.4B

RevenueRevenue Generating

Key PartnersMerck & Co. (Oncology), U.S. Government (BARDA, NIAID), CARB-X (Antimicrobial resistance)

Key InvestorsFlagship Pioneering

Commercial Products

Products on Market

3 approved products generating revenue.

mRNA-4157/V940 + KEYTRUDA®

Marketed

intismeran mudopevovec (mRNA-4157)

OncologyBiologicMRNA

mRNA-4157/V940 (intismeran mudopevovec) in combination with KEYTRUDA is the first approved personalized cancer vaccine. It uses Moderna's mRNA platform to encode up to 34 tumor-specific neoantigens unique to each patient, stimulating a targeted immune response against their cancer. Developed in partnership with Merck & Co., it received approval for adjuvant treatment of high-risk melanoma after complete surgical resection. Phase 3 trials in non-small cell lung cancer are ongoing.

Approved Indications

High-risk melanoma (post-resection)Non-small cell lung cancer (Phase 3)Other solid tumors (development)

Mechanism of Action

Individualized neoantigen therapy (INT) — personalized mRNA encoding up to 34 patient-specific neoantigens, combined with Merck's KEYTRUDA® (pembrolizumab)

First Approved

Jan 2025

mRESVIA®

Marketed

mresvia (mRNA-1345)

Infectious DiseasesVaccineMRNA

mRESVIA is Moderna's second FDA-approved product and the first mRNA-based RSV vaccine. Approved in May 2024 for adults aged 60 and older, it demonstrated 83.7% efficacy against RSV-associated lower respiratory tract disease in its pivotal Phase 3 trial (ConquerRSV). It represents a major near-term revenue growth driver for Moderna beyond its COVID-19 franchise.

Approved Indications

Respiratory Syncytial Virus (RSV) prevention in adults aged 60 and older

Mechanism of Action

mRNA encoding RSV prefusion F glycoprotein encapsulated in lipid nanoparticles

First Approved

May 2024

SPIKEVAX®

Marketed

elasomeran (mRNA-1273)

Infectious DiseasesVaccineMRNA

SPIKEVAX is Moderna's first FDA-approved product and the first mRNA vaccine to receive full FDA approval. Originally authorized under Emergency Use Authorization in December 2020, it was developed in record time (65 days from sequence to first human dose) in response to the COVID-19 pandemic. SPIKEVAX has generated over $60 billion in cumulative revenue (2021-2023) and is updated annually for emerging SARS-CoV-2 variants.

Approved Indications

COVID-19 prevention in adults and adolescentsCOVID-19 booster vaccination

Mechanism of Action

mRNA encoding SARS-CoV-2 spike protein encapsulated in lipid nanoparticles

First Approved

Jan 2022

Technology

How It Works

A step-by-step look at the technology platform powering the pipeline.

Step 1

mRNA Design & Sequence Engineering

Moderna's scientists extensively modify the nucleotide sequence (using pseudouridine, for example) to enhance translational efficiency, increase protein yield, and reduce unwanted innate immune recognition, which improves tolerability.

Step 2

Lipid Nanoparticle (LNP) Delivery System

The chemically modified mRNA is encapsulated in proprietary lipid nanoparticles. These LNPs are engineered for stability, targeted delivery to specific cells or organs (e.g., liver, muscle), and efficient cellular uptake and endosomal escape to release the mRNA into the cytoplasm for translation.

Step 3

Manufacturing Prowess

A critical, often underappreciated component is Moderna's rapid, scalable, and digitalized manufacturing process. Its mRNA medicines are produced from a DNA template in a cell-free, enzymatic process, allowing for a highly consistent and agile production system that can be leveraged across the entire portfolio.

Step 4

Core Modalities

The platform is applied through distinct therapeutic modalities: 1) Prophylactic Vaccines (e.g., SPIKEVAX), 2) Systemic Secreted & Cell Surface Therapeutics (encoding proteins for systemic circulation, e.g., for rare diseases), and 3) Intracellular Therapeutics (encoding proteins that function inside cells, e.g., for oncology).

Swipe to explore →

Platform Deep Dive

Moderna's competitive moat is built upon its proprietary and extensively optimized mRNA technology platform. Unlike traditional biologics manufacturing, which requires complex cell culture systems to produce proteins *outside* the body, mRNA turns the patient's own cells into bioreactors to produce proteins *inside* the body. This offers potential advantages in speed of development, scalability of manufacturing, and the ability to encode proteins that are difficult to produce conventionally.

The platform consists of several interconnected, patented components:

This integrated platform enables a "plug-and-play" approach where new mRNA sequences targeting different antigens or proteins can be inserted into established LNP formulations and manufacturing processes, theoretically accelerating development timelines for new candidates.

Competitive Position

Moderna faces intense competition from large pharma (Pfizer, GSK, Sanofi) in vaccines and from a diverse set of biotechs in oncology and rare diseases. Its competitive advantages are its validated, rapid mRNA platform, a strong balance sheet for investment, and strategic partnerships like the one with Merck in oncology.

Key Programs

Pipeline Highlights

Program	Indication	Phase	Status
mRNA-1345	Respiratory Syncytial Virus (RSV) in adults ≥60	Approved	Commercial
mRNA-1083	Combined Influenza + COVID-19 booster	Phase 3	Active
mRNA-1010/1011	Seasonal Influenza	Phase 3	Active
mRNA-1647 & mRNA-1230	Cytomegalovirus (CMV) prevention	Phase 3	Active
mRNA-4157 (V940) / KEYTRUDA®	Adjuvant treatment for high-risk melanoma (post-resection)	Approved	Commercial/Phase 3 in other cancers
mRNA-6231 (AZURE™)	Autoimmune disorders (e.g., Systemic Lupus Erythematosus)	Phase 2	Active
mRNA-3927	Propionic Acidemia (PA)	Phase 1/2	Active

Pipeline Map

Development Pipeline

108programs

30active

23Phase 1

1Phase 1/2

38Phase 2

23Phase 3

4Approved

Pre-clinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

Approved

Infectious Diseases

56 programs

Other

32 programs

Rare Diseases

8 programs

Oncology

2 programs

Autoimmune

1 program

Cardiovascular

1 program

Scroll to explore the pipeline →

Pipeline

Respiratory Syncytial Virus, Human Metapneumovirus

Phase 1Active

Leadership

Executive Team

Stéphane Bancel

Chief Executive Officer

Stephen Hoge, M.D.

President

Paul Burton, M.D., Ph.D.

Chief Medical Officer

Jorge Gomez

Chief Financial Officer

Arpa Garay

Chief Commercial Officer

Juan Andres

President of Strategic Partnerships and Enterprise Expansion

Noubar Afeyan, Ph.D.

Chairman of the Board

Funding

Funding History

$1.2B raised across 4 rounds.

$40.0M

Seed

Jun 2011

Flagship Pioneering

$110.0M

Series A

Jun 2013

Flagship Pioneering

$450.0M

Series B

Jun 2015

AstraZeneca

$604.0M

IPO

Dec 2018

Scroll to see all rounds →

Stock Performance

MRNA Price History

USD 48.54+100.2%

Market Cap

$20.4B

52W High

USD 484.47

52W Low

USD 12.26

Financial Context

Moderna's financial profile is characterized by a strong balance sheet built on pandemic revenue but facing a period of transition. The company reported full-year 2023 revenue of approximately $6.8 billion (a significant decline from 2022's $19.3 billion) and a net loss of $4.7 billion, as it invested heavily in R&D (~$4.8 billion) and SG&A to build its commercial infrastructure and pipeline. As of December 31, 2023, Moderna held approximately $13.3 billion in cash, cash equivalents, and investments. This substantial war chest is intended to fund operations through the anticipated launch of multiple new products (RSV, Flu, etc.) without the need for additional financing. The key financial metric to watch is the path to sustained profitability post-COVID, which will depend on the successful commercialization of its new vaccine portfolio and disciplined operational spending.

Market

Market Opportunity

Moderna is targeting several multi-billion-dollar markets. The immediate opportunity lies in respiratory vaccines. The combined annual market for COVID-19 boosters, seasonal influenza, and RSV vaccines is estimated at over $30 billion. Moderna's strategy is to capture share with best-in-class efficacy (as seen with its RSV vaccine) and drive adoption through combination products like mRNA-1083.

The latent virus vaccine segment represents a high-value, blue-sky opportunity. A successful CMV vaccine could address a significant unmet need and command a premium price. Success in EBV or HIV (where Moderna has early-stage candidates) would be transformative, both medically and commercially.

In oncology, the approval of mRNA-4157/V940 in melanoma validates the PCV approach. The global cancer therapeutics market exceeds $200 billion, and if Phase 3 trials in non-small cell lung cancer and other indications show significant benefit, Moderna's PCV platform could capture a substantial portion of the adjuvant treatment market.

The rare disease and autoimmune portfolios are longer-term bets with high risk but potentially very high reward due to the orphan drug pricing model and the chronic nature of autoimmune conditions. Success here would demonstrate mRNA's utility beyond vaccines and infectious diseases.

Risk Factors

Key Considerations

Commercial Execution Risk

Moderna must successfully launch multiple new products in competitive markets (RSV, Flu) simultaneously. Failure to gain significant market share or achieve projected pricing would jeopardize its growth narrative and path to profitability.

Pipeline Clinical & Regulatory Risk

The majority of Moderna's value is tied to unapproved candidates. Setbacks in key late-stage programs (e.g., flu vaccine, CMV vaccine, oncology trials) would significantly impact the stock and long-term prospects.

Platform Limitation Risk

While mRNA has proven superb for vaccines, its efficacy and safety in chronic therapeutic settings (rare diseases, autoimmune) remain unproven. Unexpected toxicities or insufficient durability of effect could limit the platform's broader applicability.

Patent & IP Litigation Risk

The foundational mRNA and LNP intellectual property landscape is complex and contested. Ongoing lawsuits with rivals like Pfizer/BioNTech and Arbutus create uncertainty and potential for future royalty obligations or market exclusivity challenges.

COVID Franchise Volatility

Revenue from COVID vaccines remains unpredictable and is declining faster than some anticipated, creating near-term earnings volatility and investor skepticism.

Outlook

Forward Looking

Moderna stands at a critical inflection point. The company has successfully navigated its first act—proving the mRNA platform and achieving commercial scale. Its second act is now underway: leveraging its platform, financial resources, and commercial team to build a durable, multi-product portfolio. The near-term (12-24 month) outlook hinges on the successful commercial launches of its RSV vaccine and, subsequently, its flu and combination vaccines. Positive data readouts from its CMV and oncology programs would provide significant catalysts.

The long-term thesis rests on Moderna's ability to expand the boundaries of mRNA medicine. If the company can replicate its vaccine success in therapeutic areas like oncology and rare diseases, it could evolve from a leading vaccine company into a broad-based biopharmaceutical leader. However, the risks are substantial, and the competitive pressures are intense. Investors should expect continued volatility as the market assesses the commercial uptake of new products and the clinical progress of the pipeline. Moderna's journey from pandemic hero to sustainable healthcare innovator is one of the most consequential stories to watch in the biotech sector.

Research